Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -36.97
- Piotroski Score 4.00
- Grade Buy
- Symbol (KTRA)
- Company Kintara Therapeutics, Inc.
- Price $0.22
- Changes Percentage (-6.31%)
- Change -$0.01
- Day Low $0.20
- Day High $0.24
- Year High $26.21
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/11/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.32
- Trailing P/E Ratio -0.09
- Forward P/E Ratio -0.09
- P/E Growth -0.09
- Net Income $-8,501,000
Income Statement
Quarterly
Annual
Latest News of KTRA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
The Costs Of Abandoning DEI And Why Leaders Can't Afford To Backtrack
Organizations are scaling back Diversity, Equity, and Inclusion (DEI) initiatives amid political shifts, risking systemic inequities and stifling business growth. DEI isn't just a moral imperative but...
By Forbes | 4 days ago -
BHP Backtracks Its Comments On Abandoning Anglo American Deal
At BHP's shareholder meeting, MacKenzie downplayed the Anglo American acquisition. BHP clarified it wasn't a formal withdrawal from the deal. Despite challenges in Australia, BHP aims to expand in Sou...
By Yahoo! Finance | 3 weeks ago -
Exclusive | Mark Cuban backtracks after urging Kamala Harris to fire Big Tech...
Billionaire Mark Cuban withdrew his criticism of FTC Chair Lina Khan, stating he doesn't aim to sway personnel choices in a hypothetical Harris administration. Cuban expressed concerns over Khan's app...
By New York Post | 3 weeks ago
